Refractory polymyositis responding to infliximab: extended follow-up

Authors:
  • ILI. Labioche
    I. Labioche
  • BWB. Weschler
    B. Weschler
  • VLV. Loustaud-Ratti
    V. Loustaud-Ratti
  • PSP. Soria
    P. Soria
  • EVE. Vidal
    E. Vidal

Abstract
Sir, The management of patients with dermatomyositis (DM) or polymyositis (PM) who fail to respond durably to conventional treatments remains difficult [1, 2]. We report the case of a 63-yr-old woman with refractory PM that dramatically responded to the addition of anti-TNF-α agent infliximab.